EXAS
Companies
NASDAQ
Exact Sciences Corp
Health Care
$52.99
-$3.20 (-5.69%)
Price Chart
Overview
About EXAS
exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences' noninvasive colon cancer screening test, visit cologuardtest.com
Market Cap
$7.9B
Volume
166.9M
Avg. Volume
166.9M
P/E Ratio
-165.94116
Dividend Yield
0.00%
Employees
5.9K
Company Information
Risk & Correlation Analysis
Market Correlation
1.19
Moderate Correlation
Volatility
High (0.54)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, EXAS shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$7.9B
Volume166.9M
P/E Ratio-165.94
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 2, 2025Related Securities
Pricing info last updated June 19, 2025 (after market close)Other info last updated April 2, 2025